CareLit · DOI-Nachweis · Pneumologie
Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSC…
DOI 10.1055/s-0035-1544761
Bibliografische Angaben
Nachweis in CareLit
Autor:innenM Schuler, D Planchard, JC Yang, F De Marinis, J Bennouna, JH Kim, C Chouaid, R Wiewrodt, F Grossi, J Feng, J Strausz, S Lu, DW Kim, X Liu, YM Chen, C Zhou, B Wang, VK Chand, K Park
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Continuation of EGFR inhibition beyond progression has been associated with improved disease control in case reports and retrospective/non-randomized studies. LL5 is a randomized trial, which assessed the efficacy of continuation of the irreversible ErbB family blocker, A, beyond progression with the addition of P in NSCLC pts with prior benefit from reversible EGFR tyrosine kinase inhibitors (E/G) and A…
Zitieren
Zitierempfehlung
M Schuler, D Planchard, JC Yang, F De Marinis, J Bennouna, JH Kim, C Chouaid, R Wiewrodt, F Grossi, J Feng, J Strausz, S Lu, DW Kim, X Liu, YM Chen, C Zhou, B Wang, VK Chand, K Park (2015) Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung…. Pneumologie (02). https://doi.org/10.1055/s-0035-1544761
Mit CareLit weiterarbeiten